Physician profile
Timothy Jayasundera
NPI 1811908205
$87,194.90
in general payments reported to CMS, 2019-2025
25 companies · $605 in 2025
The $605 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,034 · 2020: $16K · 2021: $37K · 2022: $15K · 2023: $9,057 · 2024: $2,362 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,650 · Food and Beverage: $2,130 · Travel and Lodging: $225 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,650.00 |
| Food and Beverage | $2,129.78 |
| Travel and Lodging | $224.71 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $43,218.19 | 2019-2025 | Farxiga, Wainua, Airsupra |
| Esperion Therapeutics, INC. | $38,768.44 | 2020-2025 | Nexletol |
| Amgen INC. | $2,760.47 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $486.04 | 2019-2025 | Avvigo Guidance System, Synergy |
| Bayer Healthcare Pharmaceuticals INC. | $186.86 | 2022-2023 | |
| Heartflow, INC. | $178.12 | 2025 | |
| Abbott Laboratories | $169.69 | 2019-2023 | Freestyle Libre 2 |
| Abiomed | $167.33 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $151.41 | 2023-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $138.03 | 2020-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $134.70 | 2019 | |
| Amarin Pharma, INC. | $129.66 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $124.75 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $96.00 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $85.90 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $70.77 | 2019 | |
| Lilly USA, LLC | $62.64 | 2019-2022 | |
| Novo Nordisk INC | $47.70 | 2019-2020 | |
| Medtronic, INC. | $46.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.28 | 2019 | |
| Shield Therapeutics INC | $37.85 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $34.27 | 2019-2020 | |
| Scpharmaceuticals INC. | $25.90 | 2023 | |
| Astellas Pharma US INC | $19.76 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jayasundera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.